Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796010 | 0.81 | RAB9A (0.47) | RAB9ANPC1THRBMAPTTDP1 | |
| SCHEMBL796534 | 0.79 | TNKS2 (0.46) | RAB9ATHRBMAPTTDP1TP53 | |
| SCHEMBL13394277 | 0.79 | TP53 (0.69) | RAB9AKDM4ETHRBRXFP1MAPT | |
| SCHEMBL84416 | 0.78 | RAB9A (0.64) | RAB9ANPC1THRBRXFP1MAPT | |
| SCHEMBL796869 | 0.78 | THRB (0.47) | RAB9ATHRBRXFP1MAPTTDP1 | |
| SCHEMBL5909037 | 0.78 | LMNA (0.53) | RAB9AKDM4ENPC1THRBRXFP1 | |
| SCHEMBL13394338 | 0.75 | KDM4E (0.38) | RAB9AKDM4EL3MBTL1NPC1THRB | |
| SCHEMBL1852674 | 0.75 | APP (0.63) | RAB9ATHRBRXFP1MAPTTDP1 | |
| SCHEMBL11012603 | 0.75 | THRB (0.51) | RAB9ATHRBMAPTTDP1TP53 | |
| SCHEMBL24105988 | 0.73 | THRB (0.50) | RAB9ATHRBMAPTTDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0605295-A1 | Derivatives of 2-thienylimidazo 2,1-b benzothiazole-3-acetic acid, their preparation and their therapeutical use | SYNTHELABO (FR) | 1994-07-06 | — | — | EP | claimed |
| JP-6234770-A | — | — | None | — | — | JP | disclosed |
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2012-03-22 | — | — | US | disclosed |
| US-5418248-A | Anticonvulsant, auxiolytic | SYNTHELABO (FR) | 1995-05-23 | — | — | US | disclosed |
| JP-H06234770-A | 2-THIENYLIMIDAZO(2,1-B)BENZOTHIAZOLE-3-ACETIC ACID DERIVATIVE, ITS PREPARATION AND APPLICATION THEREOF IN MEDICAL TREATMENT | SYNTHELABO SA | 1994-08-23 | — | — | JP | disclosed |
| EP-0605295-A1 | Derivatives of 2-thienylimidazo 2,1-b benzothiazole-3-acetic acid, their preparation and their therapeutical use | SYNTHELABO (FR) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | IAPP, APP, HTT | RAB9A 3627/4885KDM4E 4716/4885L3MBTL1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.